Taysha Gene Therapies (NASDAQ:TSHA) CFO Kamran Alam Sells 23,849 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Kamran Alam sold 23,849 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $109,943.89. Following the completion of the transaction, the chief financial officer directly owned 1,443,786 shares of the company’s stock, valued at $6,655,853.46. This represents a 1.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Kamran Alam also recently made the following trade(s):

• On Friday, January 23rd, Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00.

Taysha Gene Therapies Price Performance

TSHA opened at $4.76 on Wednesday. The firm has a market capitalization of $1.30 billion, a P/E ratio of -14.42 and a beta of 1.02. The stock has a fifty day moving average of $5.09 and a 200-day moving average of $4.08. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. JMP Securities set a $8.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. The Goldman Sachs Group set a $11.00 price objective on Taysha Gene Therapies in a research report on Thursday, December 4th. Chardan Capital restated a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research note on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Key Stories Impacting Taysha Gene Therapies

Here are the key news stories impacting Taysha Gene Therapies this week:

• Negative Sentiment: CFO Kamran Alam sold 78,968 shares on Jan. 23 at ~$4.75 and 23,849 shares on Jan. 26 at ~$4.61 (total ≈102,817 shares, ≈$485k). This reduced his stake by about 5.11% and 1.62% in the respective filings. CFO Form 4
• Negative Sentiment: CEO Sean P. Nolan sold 136,789 shares on Jan. 23 at ~$4.75 and 41,312 shares on Jan. 26 at ~$4.61 (total ≈178,101 shares, ≈$840k). These sales reduced his ownership by ~4.43% and ~1.40% in the respective filings. CEO Form 4
• Negative Sentiment: Insider Sukumar Nagendran sold 89,132 shares on Jan. 23 at ~$4.75 and 26,918 shares on Jan. 26 at ~$4.61 (total ≈116,050 shares, ≈$547k), reducing his stake by ~6.22% and ~2.00% in the respective filings. Director Form 4

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently bought and sold shares of the business. Marex Group plc bought a new position in Taysha Gene Therapies during the second quarter valued at about $29,000. E Fund Management Co. Ltd. acquired a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at about $31,000. ST Germain D J Co. Inc. raised its stake in shares of Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after acquiring an additional 4,333 shares in the last quarter. May Hill Capital LLC acquired a new stake in Taysha Gene Therapies in the 2nd quarter worth approximately $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Taysha Gene Therapies in the 3rd quarter worth approximately $40,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.